The Landscape of Asthma Research in America
Asthma research in the U.S. has shifted noticeably in the past few years. Where once the focus was almost entirely on inhaled corticosteroids and bronchodilators, the conversation now includes biologics, triple-combination therapies, and targeted approaches based on a patient's specific type of inflammation.
The approval of Breztri in April 2026 as the first triple therapy for asthma in patients aged 12 and older marked a significant moment. The Phase III KALOS and LOGOS trials behind that approval showed measurable improvements in lung function compared to dual-combination treatments. Njira Lugogo, MD, a clinical professor at the University of Michigan, noted that many patients remain at risk for exacerbations even while on dual maintenance therapy, and this is precisely the gap that newer research aims to close.
Across the country, clinical trial activity is concentrated in academic medical centers, private research clinics, and allergy and asthma specialty practices. Cities like Boston, Houston, Chicago, San Diego, and Durham host some of the most active sites, but smaller cities are increasingly part of the network. A study site in Peoria, Illinois, for instance, is currently recruiting adolescents for an asthma inhaler trial running through 2027. The geography of research is broadening, which matters for people who cannot easily travel to major metropolitan hubs.
What researchers are looking for varies by study. Some trials need participants with mild intermittent asthma. Others require people whose symptoms remain uncontrolled despite using medium-to-high-dose maintenance inhalers. A recent Phase 4 study targeting teens and adults aged 12 to 80 with uncontrolled asthma asks whether adding a new medication works better than simply increasing the dose of a current inhaler. The eligibility checklist for that study is typical of many: a confirmed asthma diagnosis for at least one year, daily use of a maintenance inhaler, and a record of symptoms that are not fully managed.
Why People Volunteer and What They Actually Experience
The reasons people give for joining a clinical trial are rarely simple. Some have cycled through every available treatment and still struggle to breathe freely. Others are motivated by the idea of contributing to medical knowledge that might help their children or grandchildren. A fair number are drawn by the practical benefits: study-related care at no cost and compensation for time and travel.
Olivia, a teenager who participated in the GenARA trial through Duke Clinical Research Institute, described using her compensation to buy shoes for a winter formal. Her mother, Sonya, who works in clinical research herself, highlighted a different benefit: the study provided a structured way to track Olivia's symptoms through the changing seasons, which was especially helpful during winter months when breathing tended to get harder. The logistics were not always easy. Finding the right time of day for study procedures took some trial and error. But the family felt the trade-off was worthwhile.
Not every story reads like Olivia's. Some participants find the visit schedule burdensome. Others never know whether they received the investigational drug or a placebo, which can be frustrating if their symptoms do not improve. These are the less glamorous parts of clinical research, and they deserve honest acknowledgment.
How Costs and Compensation Actually Work
One of the most common questions people ask is whether participating in a clinical trial costs money. The answer is generally no for the study-related procedures and medications. The sponsor covers the cost of the investigational drug, lab work, and study-specific exams. Routine care that would happen regardless of the trial is usually billed to insurance or paid out of pocket, though this varies by study design.
Compensation for participants is standard practice in the U.S., but amounts differ widely. A trial requiring weekly site visits over several months will typically offer more compensation than one with a handful of check-ins. Payment is often structured around completed visits or milestones rather than a lump sum. Some studies also reimburse for mileage, parking, and occasional meals.
The table below offers a general comparison of different trial types and what participants might expect.
| Trial Type | Typical Duration | Visit Frequency | Common Participant Profile | Key Benefits | Potential Drawbacks |
|---|
| Phase I (first-in-human) | Weeks to months | Frequent, sometimes overnight stays | Healthy volunteers or those with mild asthma | Highest compensation levels | Unknown safety profile, more invasive monitoring |
| Phase II (dose-finding) | Several months | Every 2-4 weeks | People with moderate asthma | Early access to novel mechanisms | Uncertainty about effective dose, moderate time commitment |
| Phase III (confirmatory) | 6 months to 2 years | Monthly or quarterly | Broader asthma population, often uncontrolled | Closest monitoring, established safety baseline | Large time commitment, possibility of placebo group |
| Phase IV (post-market) | Varies widely | Monthly or quarterly | Real-world patient populations | Drug already FDA-approved, lower risk | May not offer compensation equivalent to earlier phases |
| Observational studies | Months to years | Sporadic | Any asthma patient meeting criteria | No intervention risks, contributes to understanding | Typically no direct medical benefit, lower compensation |
It is worth noting that Phase IV studies, which examine drugs already on the market, have become more common in asthma research. These tend to feel less intimidating to first-time participants because the medication involved has already been through extensive safety testing.
Finding the Right Trial in Your Area
The most reliable starting point is ClinicalTrials.gov, a database maintained by the National Library of Medicine. The search function lets you filter by condition, location, age group, and study phase. Searching for "asthma" and your city or state will pull up actively recruiting trials. Each listing includes contact information for the study coordinator, a summary of eligibility criteria, and the locations where the trial is being conducted.
Beyond the federal database, allergy and asthma specialty clinics often maintain their own lists of open studies. The Midwest Allergy Sinus Asthma group, for example, runs a referral program and posts detailed recruitment information online. The American Lung Association also connects patients with research through its Airways Clinical Research Centers network, which recently began recruiting for a study on whether omalizumab can help prevent COPD flare-ups in people with allergies.
Academic medical centers are another good place to look. The Icahn School of Medicine at Mount Sinai, for instance, is conducting a pilot study on self-management support for World Trade Center responders with asthma. These niche studies address specific populations and are rarely advertised broadly, so checking university websites directly can surface opportunities that general searches miss.
When you find a trial that seems like a fit, the first step is usually a phone screening. A research coordinator will ask about your asthma history, current medications, and general health. Expect questions about how long you have been diagnosed, what maintenance inhaler you use, and whether you have had recent exacerbations requiring oral steroids or emergency care. The coordinator is also checking for exclusion criteria, which can include a history of other lung diseases, certain smoking histories, or recent respiratory infections.
Questions Worth Asking Before You Sign
The informed consent document can run to twenty pages or more, and it is easy to skim it without truly absorbing the implications. Taking the time to ask questions before signing is not just sensible—it is the whole point of the informed consent process.
What happens if my asthma worsens during the trial? Will I be able to stay on my current medications alongside the study drug? Who handles a medical emergency during the study, and how quickly can I reach someone? What does the visit schedule look like, and is there flexibility if I need to reschedule? Will I ever find out whether I received the investigational treatment or the placebo?
These questions matter because the answers shape your daily life for the duration of the study. A trial requiring weekly visits for six months is a different proposition from one with quarterly check-ins. Knowing the difference upfront prevents the kind of resentment that leads people to drop out midway.
Also worth asking: what happens when the trial ends? Some studies offer an open-label extension, meaning all participants—including those who were in the placebo group—can receive the active treatment for a period after the main study concludes. This is not guaranteed, but it is common enough to be worth inquiring about.
The Momentum in Asthma Research
The asthma research pipeline in the U.S. is notably active right now. Biologics targeting specific inflammatory pathways—omalizumab, mepolizumab, dupilumab, and others—have already changed the treatment landscape for severe asthma, and head-to-head trials comparing these drugs directly are underway. The TREAT trial, for example, is comparing omalizumab to mepolizumab and will be among the first to provide direct comparative evidence rather than relying on separate studies with different designs.
At the same time, researchers are looking beyond medications. Behavioral interventions, self-management programs, and digital tools for tracking symptoms and inhaler technique are all being tested. The idea is that asthma control is not just about what you inhale but about how you understand and respond to your own symptoms.
For anyone considering a clinical trial, the practical steps are straightforward. Search the federal database or a local research center's website. Call the coordinator. Ask the hard questions. Talk to your regular doctor about whether the study makes sense given your specific situation. There is no obligation to enroll just because you inquired.
Clinical trials are not a shortcut to better health, and they are not for everyone. But for people whose asthma has refused to cooperate with standard treatments, they represent a structured, medically supervised way to explore what might come next.
研究の知恵